Sydney Lupkin

Yeah, so the stakes are high. In October, FDA first said the shortage was over, but a trade group for the largest compounding pharmacies sued the FDA, challenging that determination. The compounders said there was no way the shortage could be over because many patients still couldn't fill their name-brand prescriptions

Yeah, so the stakes are high. In October, FDA first said the shortage was over, but a trade group for the largest compounding pharmacies sued the FDA, challenging that determination. The compounders said there was no way the shortage could be over because many patients still couldn't fill their name-brand prescriptions

Yeah, so the stakes are high. In October, FDA first said the shortage was over, but a trade group for the largest compounding pharmacies sued the FDA, challenging that determination. The compounders said there was no way the shortage could be over because many patients still couldn't fill their name-brand prescriptions

And they allege that the FDA hadn't determined how many people would need to make the switch from the compounded to the name brand drugs either. So the FDA took another look and for a second time declared the triseptide shortage resolved.

And they allege that the FDA hadn't determined how many people would need to make the switch from the compounded to the name brand drugs either. So the FDA took another look and for a second time declared the triseptide shortage resolved.

And they allege that the FDA hadn't determined how many people would need to make the switch from the compounded to the name brand drugs either. So the FDA took another look and for a second time declared the triseptide shortage resolved.

The agency says it took a look at many factors, including the drug manufacturer's inventory data, projected demand. It says it also spoke to patients, healthcare providers, and compounding pharmacies. Bottom line, the agency said it thinks Eli Lilly can make enough. Lilly said in a statement that the FDA decision reflects the company's hard work to expand its manufacturing capacity.

The agency says it took a look at many factors, including the drug manufacturer's inventory data, projected demand. It says it also spoke to patients, healthcare providers, and compounding pharmacies. Bottom line, the agency said it thinks Eli Lilly can make enough. Lilly said in a statement that the FDA decision reflects the company's hard work to expand its manufacturing capacity.

The agency says it took a look at many factors, including the drug manufacturer's inventory data, projected demand. It says it also spoke to patients, healthcare providers, and compounding pharmacies. Bottom line, the agency said it thinks Eli Lilly can make enough. Lilly said in a statement that the FDA decision reflects the company's hard work to expand its manufacturing capacity.

and meet patient needs. So compounding pharmacies will need to stop making and selling the compounded versions in February or March, depending on their size.

and meet patient needs. So compounding pharmacies will need to stop making and selling the compounded versions in February or March, depending on their size.

and meet patient needs. So compounding pharmacies will need to stop making and selling the compounded versions in February or March, depending on their size.

Yes, though the exact number is hard to pin down. I've heard from lots of patients who consider them a lifeline, and that's because many health insurers won't cover the drugs for weight loss. Medicare, for instance, is banned from covering drugs for weight loss because of an old law written at a time when having obesity was considered more of a personal failure than a health condition.

Yes, though the exact number is hard to pin down. I've heard from lots of patients who consider them a lifeline, and that's because many health insurers won't cover the drugs for weight loss. Medicare, for instance, is banned from covering drugs for weight loss because of an old law written at a time when having obesity was considered more of a personal failure than a health condition.

Yes, though the exact number is hard to pin down. I've heard from lots of patients who consider them a lifeline, and that's because many health insurers won't cover the drugs for weight loss. Medicare, for instance, is banned from covering drugs for weight loss because of an old law written at a time when having obesity was considered more of a personal failure than a health condition.

That means people without coverage will have to pay the full sticker price for the name brand drugs, and that's unaffordable for a lot of people who've turned to the cheaper compounded versions of the drugs.

That means people without coverage will have to pay the full sticker price for the name brand drugs, and that's unaffordable for a lot of people who've turned to the cheaper compounded versions of the drugs.

That means people without coverage will have to pay the full sticker price for the name brand drugs, and that's unaffordable for a lot of people who've turned to the cheaper compounded versions of the drugs.

Some are stockpiling the compounded drugs, you know, while they can. I checked in with Mary Struski, an Arizona woman who told me a few weeks ago about how she lost 50 pounds so far on compounded terzepatide. She says she and her nurse practitioner settled on a plan to buy enough terzepatide to get her through until about April.

Some are stockpiling the compounded drugs, you know, while they can. I checked in with Mary Struski, an Arizona woman who told me a few weeks ago about how she lost 50 pounds so far on compounded terzepatide. She says she and her nurse practitioner settled on a plan to buy enough terzepatide to get her through until about April.